La vendita allo scoperto per GreenBank Capital dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di GreenBank Capital. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

GreenBank Capital (OTC:GRNBF) Azioni, Report sulle vendite allo scoperto

GreenBank Capital Inc is a merchant bank. The company's operating segment include investments, software development, and mineral exploration. The company derives maximum revenue from investments. The company specializes in private equity, public listings, pre-IPO funding, corporate restructuring, mergers and acquisitions, reverse mergers, and business incubating.

GREENBANK CAPITAL INC by Greenbank Capital Inc.

GreenBank Capital Inc

Piper Sandler analyst James Fish maintains Pure Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) with a Overweight and raises the price target from $53 to $66.

News

Price Target

Analyst Ratings

PSTG

Piper Sandler Maintains Overweight on Pure Storage, Raises Price Target to $66

Piper Sandler analyst Harsh Kumar maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Overweight and raises the price target from $150 to $180.

NVDA

Piper Sandler Maintains Overweight on NVIDIA, Raises Price Target to $180

Investment of $168 million over three years will support EV purchases and charging infrastructure advancements
ComEd today announced that the Illinois Commerce Commission (ICC) has approved its second Beneficial Electrification (BE) Plan, investing approximately $168 million over a three-year period beginning in 2026. The continuation of ComEd's BE funding marks a significant step forward in ComEd's commitment to advancing electric vehicle (EV) adoption and reducing emissions in northern Illinois.
Building on its current $231 million investment in beneficial electrification, deployed from 2023 through 2025, ComEd will invest an additional $168 million between 2026-2028 through BE Plan 2 to help residential and non-residential customers transition to and take advantage of electric vehicles.
ComEd is a unit of Chicago-based Exelon Corporation (NASDAQ:<a href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>), a Fortune 200 energy company serving more than 10.7 million electricity and natural gas customers—the largest number of customers in the U.S. ComEd <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpoweringlives.comed.com%2F&amp;esheet=54262138&amp;newsitemid=20250529759823&amp;lan=en-US&amp;anchor=powers+the+lives&amp;index=12&amp;md5=b527f7006a9870da319d05bbaccf5499">powers the lives</a> of more than 4 million customers across northern Illinois, or 70 percent of the state's population.&nbsp;

Exelon's Unit ComEd Secures ICC Approval For $168M Beneficial Electrification Plan 2

<a href="https://www.reuters.com/business/autos-transportation/us-faa-extends-boeing-regulatory-delegation-program-by-three-years-2025-05-29/">https://www.reuters.com/business/autos-transportation/us-faa-extends-boeing-regulatory-delegation-program-by-three-years-2025-05-29/</a>

General

'US FAA extends Boeing regulatory delegation program by three years'- Reuters

<a href="https://www.federalreserve.gov/newsevents/pressreleases/other20250529a.htm" title="https://www.federalreserve.gov/newsevents/pressreleases/other20250529a.htm">https://www.federalreserve.gov/newsevents/pressreleases/other20250529a.htm</a>

Macro Economic Events

Politics

Economics

Federal Reserve

Fed's Powell Met With Trump At White House Today; Powell Did Not Discuss Expectations For Monetary Policy; Powell Said His Policy Will Depend On Incoming Economic Information -fed Statement

Piper Sandler analyst Jessica Tassan upgrades Claritev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTEV#NYSE">CTEV</a>) from Neutral to Overweight and raises the price target from $19 to $44.

Upgrades

CTEV

Piper Sandler Upgrades Claritev to Overweight, Raises Price Target to $44

The Board of Directors of TruGolf Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>), a leading golf technology company, today announced the authorization of a stock repurchase program of up to $2 million of TruGolf's Class A common stock.
The stock repurchase program will expire upon the expenditure of $2 million, when terminated or otherwise completed. Purchases may be made in open-market transactions or by other means as determined by TruGolf's management and in accordance with the regulations of the Securities and Exchange Commission. The timing of purchases and the number of shares repurchased under the stock repurchase program will depend on a variety of factors including price, trading volume, market conditions and corporate and regulatory requirements.

Buybacks

TRUG

TruGolf Holdings Board Authorizes Stock Repurchase Program Of Up To $2M Of Class A Common Stock

Piper Sandler analyst Mark Fitzgibbon downgrades Chain Bridge Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBNA#NYSE">CBNA</a>) from Overweight to Neutral and maintains the price target from $29 to $29.

Downgrades

CBNA

Piper Sandler Downgrades Chain Bridge Bancorp to Neutral, Maintains Price Target to $29

Shares of SharpLink Gaming Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) surged 51.8% to $44.28 during Thursday&#8217;s session, adding to a staggering 569% gain for the week after the company announced a $425 million private placement to adopt Ethereum as its <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45620524/sharplink-gaming-stock-soars-after-company-adopts-ethereum-treasury-strategy-whats-happening">primary treasury reserve asset</a>.
What To Know: The Minneapolis-based sports betting and iGaming firm will issue approximately 69 million shares at $6.15 each to a group of prominent crypto investors, including Consensys, Pantera Capital and Galaxy Digital. Consensys CEO and Ethereum co-founder Joseph Lubin will also join SharpLink's board as chairman, signaling deep blockchain alignment.
Proceeds from the deal, expected to close by May 29, will be used to <a href="https://www.benzinga.com/pressreleases/25/05/g45615020/sharplink-gaming-announces-425-000-000-private-placement-to-initiate-ethereum-treasury-strategy">purchase ETH</a> and fund general corporate needs. The move marks one of the largest treasury commitments to Ethereum by a publicly traded U.S. company.
"This is a significant milestone in SharpLink's journey," said CEO Rob Phythian. 
Lubin added that the partnership brings a "landmark opportunity" for Ethereum adoption in public markets, enhancing both financial strategy and innovation.
Read Also: <a href="https://www.benzinga.com/news/25/05/45671751/amd-stock-rises-on-nvidias-blowout-quarter-and-ai-momentum">AMD Stock Rises On Nvidia&#8217;s Blowout Quarter And AI Momentum</a>
<h2 class="wp-block-heading">How To Buy SBET Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in SharpLink Gaming&#8217;s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

Movers

SBET

SharpLink Gaming Stock Soars Over 500% This Week On Ethereum Treasury Move

Legal

Reuters Reports Second U.S. Court Blocks Trump Tariffs, In A Case Filed By A Toy Company; D.C. District Court Follows Previous Ruling In U.S. Trade Court

Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) has outperformed the market over the past 5 years by 21.52% on an annualized basis producing an average annual return of 35.36%. Currently, Dell Technologies has a market capitalization of $77.21 billion. 
Buying $100 In DELL: If an investor had bought $100 of DELL stock 5 years ago, it would be worth $452.34 today based on a price of $112.97 for DELL at the time of writing.
<h3>Dell Technologies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748537116_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

DELL

Here's How Much $100 Invested In Dell Technologies 5 Years Ago Would Be Worth Today

The U.S. Food and Drug Administration (FDA) approved Eton Pharmaceuticals, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) new drug application (NDA) for Khindivi (hydrocortisone) oral solution as a replacement therapy for pediatric patients five years of age and older with <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">adrenocortical insufficiency</a>.
Adrenocortical insufficiency, also known as adrenal insufficiency, is&nbsp;when the adrenal glands don&#8217;t produce enough hormones, particularly glucocorticoids (like cortisol) and mineralocorticoids (like aldosterone).&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44337390/specialty-pharmaceutical-eton-pharma-plans-fda-filing-for-et-600-oral-desmopressin-next-month-eyes-2026-launch" rel="noreferrer noopener">Eton Pharma Plans FDA Filing For ET-600 Oral Desmopressin Next Month, Eyes 2026 Launch</a>
Cortisol helps break down fats, proteins and carbohydrates in the body.
Khindivi comes in a 1mg/ml strength designed to eliminate the need to <a href="https://www.benzinga.com/pressreleases/25/05/g45658816/eton-pharmaceuticals-announces-u-s-fda-approval-for-khindivi-hydrocortisone-oral-solution" target="_blank" rel="noreferrer noopener">split or crush tablets</a>. It does not require refrigeration, mixing or shaking as it is a ready-to-use oral liquid solution.
Khindivi will be promoted by Eton&#8217;s existing team of pediatric endocrinology rare disease specialists. Eton currently commercializes FDA-approved Alkindi Sprinkle (hydrocortisone) oral granules for pediatric patients with adrenocortical insufficiency.
Eton estimates that there are more than 5,000 adrenal insufficiency patients in the U.S. between the ages of 5 and 17.
Khindivi will be available in the U.S. exclusively through Anovo, a specialty pharmacy.
The program provides prescription fulfillment, insurance benefits investigation, educational support, financial assistance for qualified patients and other services designed to help patients access treatment. Eton Cares will offer co-pay assistance to allow for zero-dollar co-pays for qualifying patients.
HC Wainwright writes that Khindivi could potentially become the hydrocortisone formulation of choice for patients with adrenal insufficiency and gain rapid adoption among caregivers and physicians.
Analyst Swayampakula Ramakanth projects Khindivi-associated revenues to grow to a peak of $28 million in 2030 from $3 million in 2025.
Analyst Ramakanth writes, &#8220;Based on management's strength in commercial execution to date we believe these additions could make 2025 a year of revenue inflection.&#8221;
On Thursday, the analyst raised the price target from $33 to $35, maintaining the Buy rating, accounting for the launch in June compared to the prior the beginning of 2Q25; raised peak penetration to 60% from the prior 40%, considering the ease of administration.
ETON Price Action: Eton Pharmaceuticals stock is down 4.83% at $19.11 at publication on Thursday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45669267/best-buy-whiffs-on-sales-earnings-tariff-pressures-mount" target="_blank" rel="noreferrer noopener">Best Buy Falls Short: Sales, Earnings Miss As Tariff Pressures Mount</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Government

Health Care

ETON

FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue

U.S.-listed Chinese stocks&nbsp;led by&nbsp;Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>),&nbsp;PDD Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), and&nbsp;Baidu, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>)&nbsp;gained on Thursday after a <a target="_blank" href="https://www.benzinga.com/25/05/45664572/us-stocks-likely-to-open-higher-after-federal-court-invalidates-trumps-tariffs-without-tariff-revenues-there-is-a-big-beautiful-hole-in-the-big-beautiful-budget-bill-says-expert" rel="noreferrer noopener">federal court invalidated</a> global tariffs&nbsp;enacted by President&nbsp;Donald Trump under the International Emergency Economic Powers Act on Wednesday.
A three-judge panel, with appointees from the Reagan, Obama and Trump eras, ruled that the IEEPA doesn&#8217;t give the president unlimited power to impose tariffs.
Reportedly, the Trump administration filed an appeal against the ruling in minutes.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/05/45620670/alibaba-eyes-growth-in-other-markets-as-us-ties-strained-says-chairman" rel="noreferrer noopener">Alibaba Eyes Growth In Other Markets As US Ties Strained, Says Chairman</a>
The Chinese electric vehicle companies, including&nbsp;NIO Inc&nbsp;(NYSE:&nbsp;NIO) and XPeng Inc (NYSE: XPEV), also noted strong upward momentum.
On May 12, Beijing and Washington <a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45348699/us-listed-chinese-stocks-rally-as-countries-agree-to-ease-import-tariffs" rel="noreferrer noopener">agreed to lower</a> tariffs on each other&#8217;s products, temporarily offering relief to the stock market. The deal reduced U.S. levies of 145% on most Chinese imports to 30%, while China&#8217;s 125% duties on U.S. goods will drop to 10% for 90 days.
In April, President Trump&nbsp;hinted at a&nbsp;significant&nbsp;reduction in&nbsp;tariff rates.
During an investor summit, Treasury Secretary Scott Bessent&nbsp;acknowledged the impracticability and mutual challenges of a tariff war with China.
U.S. chip designer Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) reported <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45657660/nvidia-q1-highlights-china-export-ban-hits-results-but-jensen-huang-says-demand-incredibly-strong" rel="noreferrer noopener">first-quarter results</a> on Wednesday. It faced an export ban on H20 products to China on April 9.
The company said it incurred a $4.5 billion charge in the first quarter related to H20 excess inventory and purchase obligations.
Price Actions:&nbsp;BABA stock is up 0.50%, and PDD is up 1.20%&nbsp;at&nbsp;the last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/large-cap/25/05/45655158/paris-air-show-2025-could-set-the-tone-for-global-aerospace-talks" target="_blank" rel="noreferrer noopener">Will Paris Air Show Signal Shift In Aerospace Trade? Analyst Flags EU Tariff Risks, Order Delays</a></li>
</ul>

Asia

Regulations

Tech

BABA

BIDU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

XPEV

Chinese Stocks Soar As US Court Blocks Trump Tariffs

Live On CNBC, Josh Brown Hosts Segment Titled "Best Stock Spotlight: Darden"

Oppenheimer analyst Timothy Horan maintains C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) with a Outperform and lowers the price target from $56 to $45.

Oppenheimer Maintains Outperform on C3.ai, Lowers Price Target to $45

Oppenheimer analyst Jeff Jones maintains Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) with a Outperform and lowers the price target from $20 to $15.

YMAB

Oppenheimer Maintains Outperform on Y-mAbs Therapeutics, Lowers Price Target to $15

Oppenheimer analyst Andreas Argyrides maintains InflaRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFRX#NASDAQ">IFRX</a>) with a Outperform and lowers the price target from $6 to $3.

IFRX

Oppenheimer Maintains Outperform on InflaRx, Lowers Price Target to $3

Oppenheimer analyst Brian Schwartz maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Outperform and lowers the price target from $380 to $370.

Oppenheimer Maintains Outperform on Salesforce, Lowers Price Target to $370

Editor&#8217;s note: This story has been corrected to reflect accurate analyst changes on Thursday.
HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) stock is trading lower Thursday after the company reported worse-than-expected earnings for the second quarter. Multiple analysts lowered price targets on the stock <a href="https://www.benzinga.com/news/earnings/25/05/45659418/hp-stock-tumbles-as-q2-earnings-fall-short-of-estimates-guidance-comes-in-soft-due-to-higher-costs-related-to-tariffs">following the report</a>.
What To Know: HP reported adjusted earnings per share of 71 cents, missing the consensus estimate of 80 cents. In addition, the company reported sales of $13.22 billion, beating the consensus estimate of $13.15 billion, and representing a 3.3% year-over-year increase.
&#8220;In&nbsp;Q2, we delivered solid revenue growth, led by strong Commercial performance in Personal Systems and continued momentum behind our future of work strategy,&#8221; said Enrique Lores, President and CEO of HP.
&#8220;While results in the quarter were impacted by a dynamic regulatory environment, we responded quickly to accelerate the expansion of our manufacturing footprint and further reduce our cost structure. These decisive actions strengthen our foundation and position us to deliver long-term sustainable growth.&#8221;
Outlook: The company sees third-quarter adjusted earnings per share from 68 cents to 80 cents, versus the consensus estimate of 90 cents. 
HP now expects fiscal-year adjusted earnings per share of $3.00 to $3.30, versus the consensus estimate of $3.49. The company previously anticipated adjusted earnings per share of $3.45 to $3.75.
&#8220;In light of the increased macroeconomic uncertainty, we have adjusted our&nbsp;outlook&nbsp;to reflect&nbsp;moderated demand and the net impact of trade-related costs,&#8221; said Karen Parkhill, CFO of HP.
Following the company&#8217;s quarterly results, analysts from Citigroup, Morgan Stanley, Barclays and JPMorgan lowered price targets ranging from $26 to $28.
HPQ Price Action: At the time of publication, HP stock was down 7.67% at $25.12, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwiO5IDp8MiNAxXFj4kEHa5hKeAQFnoECAoQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/05/45671751/amd-stock-rises-on-nvidias-blowout-quarter-and-ai-momentum">AMD Stock Rises On Nvidia&#8217;s Blowout Quarter And AI Momentum</a></li>
</ul>
Image: Shutterstock.

Earnings

Guidance

HP Stock Is Sliding Thursday: What's Going On? (CORRECTED)

Hormel Foods Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRL#NYSE">HRL</a>) shares are <a href="https://www.benzinga.com/movers" target="_blank" rel="noreferrer noopener">trading lower on Thursday.</a>
The company reported second-quarter adjusted earnings per share of 35 cents, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45664815/hormel-foods-reports-second-quarter-fiscal-2025-results" rel="noreferrer noopener">beating the Street view of 34 cents.</a>
Quarterly sales of $2.90 billion (+0.4% year over year) missed the analyst consensus estimate of $2.91 billion. Organic net sales were up by 1%.
Gross profit in the quarter under review decreased to $484.433 million from $503.806 million a year ago.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45663459/dow-dips-more-than-200-points-investor-sentiment-declines-but-fear-greed-index-remains-in-greed-zone" rel="noreferrer noopener">Dow Dips More Than 200 Points; Investor Sentiment Declines, But Fear &amp; Greed Index Remains In &#8216;Greed&#8217; Zone</a>
International segment profit decreased as a temporary shift in export customer mix and <a href="https://s204.q4cdn.com/636391999/files/doc_earnings/2025/q2/supplemental-info/q2-earnings-supplemental-deck.pdf" target="_blank" rel="noreferrer noopener">softness </a>in Brazil primarily offset meaningful net sales growth.
Retail sales inched lower by 0.3% year over year to $1.783 billion, Food service sales gained 0.5% year over year to $936.44 million, and International sales gained 7% to $178.53 million.
Adjusted operating income in the quarter under review was $264.90 million, lower than $275.91 million. Adjusted Operating Margin in the quarter under review decreased to 9.1% from 9.6% in the year-ago period.
The company exited the quarter with cash and equivalents worth $669.69 million.
Inventories surged to $1.729 billion from $1.576 billion at the end of Oct. 27, 2024.
&#8220;We anticipate strong second-half growth,&#8221; said CEO Jim Snee, highlighting contributions from the turkey portfolio, continued momentum in the Planters brand, growth from leading positions in the marketplace, and ongoing benefits from Transform and Modernize.
Outlook: Hormel Foods narrowed its FY2025 adjusted EPS guidance to $1.58–$1.68 from the prior range of $1.58–$1.72, compared to the $1.61 estimate.
The company raised its FY2025 sales outlook to $12 billion–$12.20 billion from $11.90 billion–$12.20 billion, versus the $12.12 billion estimate.
HRL Price Action: Hormel shares are trading lower by 0.92% to $29.77 at publication on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45641430/jim-cramer-says-this-quantum-computing-stock-is-so-high-and-too-speculative" target="_blank" rel="noreferrer noopener">Jim Cramer Says This Quantum Computing Stock Is ‘So High' And ‘Too Speculative'</a></li>
</ul>
Photo: Viewimage via Shutterstock

Comments

GreenBank Capital

Vendite allo scoperto

GreenBank Capital (OTC:GRNBF) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO